AOBiome

AOBiome is a private, clinical-stage biotech leveraging a single strain of ammonia-oxidizing bacteria (AOB) as a therapeutic platform to treat inflammatory skin diseases. Its lead program, B244, is in Phase 3 for atopic dermatitis, with additional Phase 2 programs in acne, eczema, and rosacea. The company's core thesis is that reintroducing this evolutionarily lost bacterium can restore immune functionality, offering a novel mechanism that simultaneously downregulates multiple inflammatory pathways implicated in itch and inflammation.

Proprietary platform based on a single strain of ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha (B244). The bacteria metabolize ammonia to produce nitric oxide and nitrite, which modulate immune response by downregulating key inflammatory cytokines (IL-4, IL-5, IL-13, IL-31), improving skin barrier function, and lowering local pH.

AOBiome competes in the crowded inflammatory skin disease market against large pharmaceutical companies with systemic biologics (e.g., Dupixent) and JAK inhibitors, as well as other topical therapies. Its primary differentiation is its novel mechanism of action as a topical, multi-cytokine modulator via a restored commensal bacterium, positioning it uniquely within the broader microbiome therapeutics competitive set.